159 related articles for article (PubMed ID: 35580321)
1. Relative hypercoagulation induced by suppressed fibrinolysis after tisagenlecleucel infusion in malignant lymphoma.
Yamasaki-Morita M; Arai Y; Ishihara T; Onishi T; Shimo H; Nakanishi K; Nishiyama Y; Jo T; Hiramatsu H; Mitsuyoshi T; Mizumoto C; Kanda J; Nishikori M; Kitawaki T; Nogami K; Takaori-Kondo A; Nagao M; Adachi S
Blood Adv; 2022 Jul; 6(14):4216-4223. PubMed ID: 35580321
[TBL] [Abstract][Full Text] [Related]
2. Chylothorax after chimeric antigen receptor T cell therapy for relapsed and refractory diffuse large B-cell lymphoma: A case report.
Chen HH; Kuo CY; Ho CL; Chen YC
Medicine (Baltimore); 2023 Oct; 102(41):e35432. PubMed ID: 37832125
[TBL] [Abstract][Full Text] [Related]
3. [Cellular kinetics and outcome of tisagenlecleucel for diffuse large B-cell lymphoma].
Hanajiri R; Furukawa K; Nakashima M; Ushijima Y; Shimada K; Ishikawa Y; Terakura S; Murata M; Kiyoi H
Rinsho Ketsueki; 2023; 64(3):167-174. PubMed ID: 37019669
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
Caimi PF; Pacheco Sanchez G; Sharma A; Otegbeye F; Ahmed N; Rojas P; Patel S; Kleinsorge Block S; Schiavone J; Zamborsky K; Boughan K; Hillian A; Reese-Koc J; Maschan M; Dropulic B; Sekaly RP; de Lima M
Front Immunol; 2021; 12():745320. PubMed ID: 34712233
[TBL] [Abstract][Full Text] [Related]
5. [Tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma: real-world data from single institute experience].
Yagi Y; Kanemasa Y; Sasaki Y; Hayashi Y; Mino M; Kato C; Sakai S; Ohigashi A; Kanbara Y; Morita Y; Tamura T; Atsuta Y; Konuma R; Nakamura S; Wada A; Okuya T; Kageyama A; Murakami D; Nakashima S; Uchibori Y; Onai D; Hamamura A; Nishijima A; Omuro Y; Shingai N; Shimizuguchi T; Toya T; Shimizu H; Najima Y; Kobayashi T; Haraguchi K; Ohashi K; Doki N; Okuyama Y; Shimoyama T
Rinsho Ketsueki; 2022; 63(10):1363-1372. PubMed ID: 36351641
[TBL] [Abstract][Full Text] [Related]
6. Individual Patient Data Meta-Analysis from 16 Trials for Safety Factors in Cytokine Release Syndrome After CAR-T Therapy in Patients with Non-Hodgkin Lymphoma (NHL) and Acute Lymphoblastic Leukemia.
Li J; Wu Z; Zhao N
Adv Ther; 2019 Oct; 36(10):2881-2894. PubMed ID: 31428935
[TBL] [Abstract][Full Text] [Related]
7. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.
Kochenderfer JN; Dudley ME; Kassim SH; Somerville RP; Carpenter RO; Stetler-Stevenson M; Yang JC; Phan GQ; Hughes MS; Sherry RM; Raffeld M; Feldman S; Lu L; Li YF; Ngo LT; Goy A; Feldman T; Spaner DE; Wang ML; Chen CC; Kranick SM; Nath A; Nathan DA; Morton KE; Toomey MA; Rosenberg SA
J Clin Oncol; 2015 Feb; 33(6):540-9. PubMed ID: 25154820
[TBL] [Abstract][Full Text] [Related]
10. Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy.
Kochenderfer JN; Somerville RPT; Lu T; Yang JC; Sherry RM; Feldman SA; McIntyre L; Bot A; Rossi J; Lam N; Rosenberg SA
Mol Ther; 2017 Oct; 25(10):2245-2253. PubMed ID: 28803861
[TBL] [Abstract][Full Text] [Related]
11. Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL.
Awasthi R; Pacaud L; Waldron E; Tam CS; Jäger U; Borchmann P; Jaglowski S; Foley SR; van Besien K; Wagner-Johnston ND; Kersten MJ; Schuster SJ; Salles G; Maziarz RT; Anak Ö; Del Corral C; Chu J; Gershgorin I; Pruteanu-Malinici I; Chakraborty A; Mueller KT; Waller EK
Blood Adv; 2020 Feb; 4(3):560-572. PubMed ID: 32045475
[TBL] [Abstract][Full Text] [Related]
12. Plasma Exchange Can Be an Alternative Therapeutic Modality for Severe Cytokine Release Syndrome after Chimeric Antigen Receptor-T Cell Infusion: A Case Report.
Xiao X; He X; Li Q; Zhang H; Meng J; Jiang Y; Deng Q; Zhao M
Clin Cancer Res; 2019 Jan; 25(1):29-34. PubMed ID: 30322878
[TBL] [Abstract][Full Text] [Related]
13. The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma.
Ali S; Kjeken R; Niederlaender C; Markey G; Saunders TS; Opsata M; Moltu K; Bremnes B; Grønevik E; Muusse M; Håkonsen GD; Skibeli V; Kalland ME; Wang I; Buajordet I; Urbaniak A; Johnston J; Rantell K; Kerwash E; Schuessler-Lenz M; Salmonson T; Bergh J; Gisselbrecht C; Tzogani K; Papadouli I; Pignatti F
Oncologist; 2020 Feb; 25(2):e321-e327. PubMed ID: 32043764
[TBL] [Abstract][Full Text] [Related]
14. Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome.
Bhaskar ST; Patel VG; Porter DL; Schuster SJ; Nastoupil LJ; Perales MA; Tomas AA; Bishop MR; McGuirk JP; Maziarz RT; Chen AI; Bachanova V; Maakaron JE; Riedell PA; Oluwole OO
Blood Adv; 2023 Sep; 7(17):4765-4772. PubMed ID: 36508286
[TBL] [Abstract][Full Text] [Related]
15. [Coagulopathy related to CAR-T cell therapy].
Arai Y
Rinsho Ketsueki; 2022; 63(9):1205-1211. PubMed ID: 36198546
[TBL] [Abstract][Full Text] [Related]
16. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Schuster SJ; Bishop MR; Tam CS; Waller EK; Borchmann P; McGuirk JP; Jäger U; Jaglowski S; Andreadis C; Westin JR; Fleury I; Bachanova V; Foley SR; Ho PJ; Mielke S; Magenau JM; Holte H; Pantano S; Pacaud LB; Awasthi R; Chu J; Anak Ö; Salles G; Maziarz RT;
N Engl J Med; 2019 Jan; 380(1):45-56. PubMed ID: 30501490
[TBL] [Abstract][Full Text] [Related]
17. Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial.
Schuster SJ; Maziarz RT; Rusch ES; Li J; Signorovitch JE; Romanov VV; Locke FL; Maloney DG
Blood Adv; 2020 Apr; 4(7):1432-1439. PubMed ID: 32271899
[TBL] [Abstract][Full Text] [Related]
18. Tisagenlecleucel infusion in patients with relapsed/refractory ALL and concurrent serious infection.
Hall EM; Yin DE; Goyal RK; Ahmed AA; Mitchell GS; St Peter SD; Flatt TG; Ahmed IA; Li W; Hendrickson RJ; August KJ; Myers GD
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33472856
[TBL] [Abstract][Full Text] [Related]
19. Late haemophagocytic lymphohistiocytosis in a patient treated with Axicabtagene ciloleucel.
Cutini I; Puccini B; Fabbri A; Santi R; Gozzini A; Nozzoli C; Boncompagni R; Innocenti C; Saccardi R
Transpl Immunol; 2022 Dec; 75():101719. PubMed ID: 36116729
[TBL] [Abstract][Full Text] [Related]
20. Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma.
Chow VA; Shadman M; Gopal AK
Blood; 2018 Aug; 132(8):777-781. PubMed ID: 29914976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]